NanoViricides’ NV-387 shows potent anti-measles activity, highlighting broad-spectrum potential

Nanoviricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share major progress in the company’s antiviral research, announcing that its clinical lead drug NV-387 has demonstrated potent activity against the Measles virus in both cell culture studies and a humanized animal model. Notably, the treatment also protected lung tissue, a critical factor in preventing death from severe, late-stage viral infections. Currently, there are no approved drugs for treating Measles, making these findings especially significant amid rising global outbreaks. Dr. Diwan explained that NV-387 produced direct antiviral effects in standard Cytopathic Effects assays, where treated cells showed increased survival compared to untreated controls. In the lethal Measles infection model, NV-387 treatment extended survival by 130% — from 7.4 days in untreated animals to 17 days in treated ones — underscoring its strong therapeutic potential. Importantly, NV-387 has already completed Phase I human trials, demonstrating no reportable adverse events and confirming that the drug is safe and well tolerated in healthy subjects. Dr. Diwan added that NanoViricides is now positioned to support emergency use applications of NV-387 for Measles patients under FDA guidelines. The company is also open to Physician’s Investigator-Initiated INDs for treating individual or small groups of patients in urgent cases. NV-387 is formulated as oral gummies, which dissolve slowly in the mouth and do not require swallowing — a key advantage for patients suffering from rashes or throat irritation associated with Measles infection. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc #measles #NanoViricides #NV387 #AntiviralDrug #MeaslesTreatment #RSV #Mpox #BroadSpectrumAntiviral #BiotechNews #ClinicalTrials #ProactiveInvestors